Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney loop of Henle epithelial cell | 4 studies | 39% ± 13% | |
kidney distal convoluted tubule epithelial cell | 4 studies | 38% ± 13% | |
renal alpha-intercalated cell | 4 studies | 38% ± 17% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney | 3 studies | 32% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 6583.30 | 89 / 89 | 96% | 28.67 | 866 / 901 |
thymus | 100% | 2377.42 | 653 / 653 | 83% | 10.17 | 501 / 605 |
pancreas | 100% | 391.51 | 327 / 328 | 72% | 24.01 | 129 / 178 |
stomach | 86% | 5316.26 | 307 / 359 | 69% | 10.98 | 196 / 286 |
lung | 74% | 215.83 | 428 / 578 | 47% | 6.52 | 544 / 1155 |
intestine | 41% | 96.32 | 394 / 966 | 65% | 7.92 | 342 / 527 |
liver | 50% | 155.48 | 114 / 226 | 54% | 6.85 | 219 / 406 |
eye | 0% | 0 | 0 / 0 | 89% | 10.81 | 71 / 80 |
bladder | 52% | 76.76 | 11 / 21 | 25% | 2.04 | 125 / 504 |
ovary | 19% | 15.48 | 35 / 180 | 54% | 3.57 | 231 / 430 |
heart | 66% | 78.11 | 570 / 861 | 0% | 0 | 0 / 0 |
uterus | 44% | 74.75 | 75 / 170 | 17% | 1.24 | 79 / 459 |
skin | 12% | 8.35 | 221 / 1809 | 46% | 4.75 | 217 / 472 |
lymph node | 0% | 0 | 0 / 0 | 55% | 3.90 | 16 / 29 |
esophagus | 16% | 24.98 | 229 / 1445 | 39% | 12.57 | 71 / 183 |
prostate | 47% | 44.30 | 114 / 245 | 4% | 0.18 | 22 / 502 |
breast | 36% | 62.51 | 167 / 459 | 6% | 0.37 | 62 / 1118 |
spleen | 38% | 52.49 | 92 / 241 | 0% | 0 | 0 / 0 |
adipose | 38% | 71.31 | 456 / 1204 | 0% | 0 | 0 / 0 |
brain | 22% | 20.53 | 575 / 2642 | 2% | 0.11 | 12 / 705 |
blood vessel | 18% | 20.00 | 237 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 3% | 3.27 | 9 / 258 | 3% | 0.21 | 6 / 230 |
muscle | 5% | 3.98 | 43 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 3% | 2.87 | 31 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.07 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051923 | Biological process | sulfation |
GO_0009308 | Biological process | amine metabolic process |
GO_0005764 | Cellular component | lysosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0004062 | Molecular function | aryl sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SULT1C2 |
Protein name | Sulfotransferase (EC 2.8.2.-) Sulfotransferase 1C2 (ST1C2) (EC 2.8.2.1) (Sulfotransferase 1C1) (SULT1C#1) (humSULTC2) |
Synonyms | SULT1C1 |
Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of phenolic compounds. Does not sulfonate steroids, dopamine, acetaminophen, or alpha-naphthol . Catalyzes the sulfonation of the carcinogenic N-Hydroxy-2-acetylaminofluorene leading to highly reactive intermediates capable of forming DNA adducts, potentially resulting in mutagenesis . . |
Accessions | C9JSR0 B4DLP0 ENST00000437390.6 H7C420 H7BZ17 ENST00000409067.2 ENST00000442801.5 ENST00000409880.5 ENST00000438339.5 O00338 B8ZZF7 ENST00000251481.11 [O00338-1] ENST00000326853.9 [O00338-2] |